CEO Samarth Kulkarni sold 60,000 shares, impacting CRISPR Therapeutics AG's (NASDAQ:CRSP) stock performance.The stock experienced a 4.71% decline recently, contrasting with the broader market's gains.Upcoming earnings report expected to show a significant decrease in EPS and revenue, highlighting financial challenges.CRISPR Therapeutics AG (NASDAQ:CRSP) is a biotechnology company focused on developing transformative gene-based medicines. The company is a leader in CRISPR/Cas9 gene-editing technology, which ...